• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

皮肤科医生与儿科医生治疗轻至中度痤疮的成本效益分析。

Cost-effectiveness analysis of using dermatologists versus pediatricians to treat mild to moderate acne.

作者信息

Davis Scott A, Himmler Sebastian, Feldman Steven R

机构信息

Division of Pharmaceutical Outcomes and Policy, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina.

出版信息

Dermatol Online J. 2017 May 15;23(5):13030/qt0p516268.

PMID:28537857
Abstract

OBJECTIVE

To assess the cost-effectiveness from the payer perspective of using dermatologists versus pediatricians to treat acne in adolescents ages 10-18.

METHODS

A Markov model was constructed to explore outcomes over a 2-year period from the US private payer perspective. Patients ages 10-18 with acne entered the model under the "dermatologist"and "pediatrician" conditions. In each 3-month cycle,each modeled patient received topical retinoids,benzoyl peroxide (BP), antibiotics, or no treatment,and could progress to an acne-free state or remain in an acne state.

RESULTS

The average patient spent42.3% of the time in acne-free states under the dermatologist condition and 28.0% of the time in acne-free states under the pediatrician condition.The cohort of 1000 patients experienced 1900 total quality-adjusted life years (QALYs) at a cost of $2.33 million in the dermatologist condition and 1883 total QALYs at a cost of $1.62 million in the pediatrician condition, yielding an ICER of $40,000/QALY. Most sensitivity analyses confirmed the base case results.

CONCLUSION

Dermatologist treatment appears cost-effective related to producing additional QALYs at a cost of less than $100,000 per QALY gained. Health plans should consider creating incentives to direct enrollees to dermatologists for acne treatment.

摘要

目的

从支付方的角度评估由皮肤科医生而非儿科医生治疗10 - 18岁青少年痤疮的成本效益。

方法

构建一个马尔可夫模型,从美国私人支付方的角度探究两年期间的治疗结果。10 - 18岁的痤疮患者在“皮肤科医生”和“儿科医生”两种情况下进入模型。在每3个月的周期中,每个模拟患者接受外用维甲酸、过氧化苯甲酰(BP)、抗生素治疗或不接受治疗,并可能进展到无痤疮状态或保持痤疮状态。

结果

在皮肤科医生治疗情况下,平均患者处于无痤疮状态的时间占42.3%,在儿科医生治疗情况下,这一比例为28.0%。1000名患者的队列在皮肤科医生治疗情况下共获得1900个质量调整生命年(QALY),成本为233万美元,在儿科医生治疗情况下共获得1883个QALY,成本为162万美元,增量成本效果比为40,000美元/QALY。大多数敏感性分析证实了基础案例结果。

结论

皮肤科医生的治疗方案似乎具有成本效益,因为每获得一个QALY的成本低于10万美元就能产生额外的QALY。健康计划应考虑制定激励措施,引导参保人找皮肤科医生治疗痤疮。

相似文献

1
Cost-effectiveness analysis of using dermatologists versus pediatricians to treat mild to moderate acne.皮肤科医生与儿科医生治疗轻至中度痤疮的成本效益分析。
Dermatol Online J. 2017 May 15;23(5):13030/qt0p516268.
2
Differences in acne treatment prescribing patterns of pediatricians and dermatologists: an analysis of nationally representative data.儿科医生和皮肤科医生痤疮治疗处方模式的差异:基于全国代表性数据的分析
Pediatr Dermatol. 2008 Nov-Dec;25(6):635-9. doi: 10.1111/j.1525-1470.2008.00790.x.
3
Clinical inquiries. What is the best treatment for mild to moderate acne?临床咨询。轻至中度痤疮的最佳治疗方法是什么?
J Fam Pract. 2006 Nov;55(11):994-6.
4
Antibiotic resistance and acne: where we stand and what the future holds.抗生素耐药性与痤疮:我们目前的状况及未来趋势
J Drugs Dermatol. 2014 Jun;13(6):s66-70.
5
Treatment of preadolescent acne in the United States: an analysis of nationally representative data.美国青春期前痤疮的治疗:基于全国代表性数据的分析
Pediatr Dermatol. 2013 Nov-Dec;30(6):689-94. doi: 10.1111/pde.12201. Epub 2013 Jul 22.
6
Differences in acne therapy prescribing patterns between dermatologists and pediatricians: A population-based study.皮肤科医生和儿科医生在痤疮治疗处方模式上的差异:一项基于人群的研究。
Pediatr Dermatol. 2021 Sep;38(5):1150-1156. doi: 10.1111/pde.14778. Epub 2021 Sep 13.
7
Emerging topical antimicrobial options for mild-to-moderate acne: a review of the clinical evidence.轻度至中度痤疮的新型局部抗菌治疗选择:临床证据综述
J Drugs Dermatol. 2008 Feb;7(2 Suppl):s2-7.
8
Acne: an approach to therapy for the pediatrician.
Curr Probl Pediatr. 1984 May;14(5):1-36.
9
Evidence-based recommendations for the diagnosis and treatment of pediatric acne.循证推荐的儿童痤疮诊断和治疗建议。
Pediatrics. 2013 May;131 Suppl 3:S163-86. doi: 10.1542/peds.2013-0490B.
10
Topical antimicrobial treatment of acne vulgaris: an evidence-based review.寻常痤疮的局部抗菌治疗:基于证据的综述。
Am J Clin Dermatol. 2012 Jun 1;13(3):141-52. doi: 10.2165/11597880-000000000-00000.

引用本文的文献

1
Cost-effectiveness analysis of targeted-release formulation of budesonide (Tarpeyo) in conjunction with optimized renin-angiotensin system inhibitor (RASi) therapy relative to optimized RASi therapy alone for adults with primary immunoglobulin A nephropathy in the United States.在美国,布地奈德(Tarpeyo)靶向释放制剂联合优化肾素-血管紧张素系统抑制剂(RASi)治疗相对于单独使用优化RASi治疗对原发性免疫球蛋白A肾病成人患者的成本效益分析。
J Manag Care Spec Pharm. 2025 May;31(5):499-509. doi: 10.18553/jmcp.2025.31.5.499.